Anthropic's "AI for Science" Event:
John Jumper, Claude, and Drug Discovery at 10x Speed

The Briefing: AI for Science runs June 30, 2026 at 10:00 AM PST (1:00 AM CST July 1) from San Francisco, streamed globally.

Who's speaking?

When Novartis and BMS CEOs share a stage at an AI company's event, it signals where pharmaceutical R&D is actually heading — not a marketing stunt.

Common pain points:

• 12–15 year timelines, $2.6B+ per drug: Only ~10% of clinical candidates reach approval.
• Tool fragmentation: Literature, ELN data, and trial registries live in silos.
• Model access blocked: Mythos 5 remains restricted under US export controls for most international teams.
• Generic chatbots lack connectors: No native Benchling, PubMed, or FDA-compliant drafting workflows.

John Michael Jumper was born in 1985 in Little Rock, Arkansas. He studied math and physics at Vanderbilt (2007), earned an MPhil in physics at Cambridge on a Marshall Scholarship (2008), and completed a PhD in theoretical chemistry at the University of Chicago (2017).

Six months after his PhD, he joined Google DeepMind on a secret project: predicting how proteins fold into 3D structures — a problem that had stumped biologists since the 1970s.

At CASP14 in 2020, AlphaFold 2 achieved accuracy matching experimental methods in hours instead of months.

AlphaFold by the numbers:

• 214 million+ protein structures predicted
• 2 million+ researchers across 190+ countries
• Accelerated drug discovery, cancer research, and fundamental biology worldwide

In 2024, Jumper and Demis Hassabis won the Nobel Prize in Chemistry (with UW's David Baker). At 39, Jumper became the youngest chemistry laureate in over 70 years.

On June 19, 2026, Jumper posted on X: "After nearly nine years, I have decided to leave Google DeepMind and join Anthropic." Hassabis responded publicly that AlphaFold had changed the world and shown AI's potential in science and medicine.

His announcement came 11 days before today's briefing. Anthropic has not disclosed his role. Given April's Coefficient Bio acquisition and Claude for Life Sciences momentum, he likely shapes foundational biology AI — possibly a next-gen protein tool along the lines of "ClaudeFold."

Claude for Life Sciences is an enterprise stack built on Claude Enterprise with MCP connectors and Agent Skills wired into tools scientists already use.

Coverage spans early discovery through regulatory submissions: literature synthesis, hypothesis generation, experimental design, genomics QC, clinical protocol drafting, and FDA query responses.

Drug design: 10x faster, fully autonomous. In internal testing, Mythos 5 accelerated key drug design steps approximately 10x. With protein design and bioinformatics tools but no human assistance, the model:

1. Chose binding sites
2. Selected and ran protein design tools
3. Recovered from failures on its own
4. Produced viable drug candidates

Result: 9 out of 14 protein targets yielded strong candidates under investigation — immune checkpoints, growth-factor signaling, neurodegeneration, muscle disease, and complex structural targets.

On AAV capsid assembly prediction (Dyno Therapeutics data), Mythos 5 outperformed dedicated protein language models built for that task.

In blind comparisons, reviewers preferred Mythos 5 hypotheses roughly 80% of the time over the previous Opus generation. One hypothesis identifying an E. coli antimicrobial target has been validated in lab testing.

Left running for one week unsupervised on a genomics project, Mythos 5 assembled single-cell data from 138 animal species and millions of cells, trained a custom ML model 100x smaller than a recent Science publication — with better performance.

Novo Nordisk (Ozempic maker): CSRs took months to draft. They built NovoScribe on Claude via Amazon Bedrock + RAG with expert-approved templates. Waheed Jowiya, Digitalization Strategy Director: "Claude has helped us cut writing times on CSRs by 90%." Expansion covers device protocols, patient materials, and full Common Technical Document automation.

Other deployments: Sanofi, AbbVie, AstraZeneca, Genmab, Bristol Myers Squibb, Komodo Health, and Axiom (toxicity prediction via Claude Code + MCP).

In April 2026, Anthropic acquired stealth startup Coefficient Bio for ~$400 million in stock. Founders Samuel Stanton and Nathan C. Frey came from Genentech Prescient Design. Their goal: ASI for Science in biology. Investor Dimension reportedly achieved 38,513% IRR on the deal. The team now sits under Eric Kauderer-Abrams, bringing protein design and biomolecule modeling depth.

Anthropic's edge vs OpenAI and DeepMind:

1. Safety-first culture — Constitutional AI aligns with pharma compliance needs
2. Vertical integration — connectors, Coefficient Bio, and Jumper's scientific credibility
3. Locked-in enterprise customers — Novartis, BMS, Genentech, Novo Nordisk

Export controls as of June 30:

• Jun 12: US government forced Fable 5 and Mythos 5 offline; foreign nationals blocked
• Jun 26: Commerce partially restored Mythos 5 for ~100 vetted US organizations
• Fable 5 public access still down; general access not restored

International pharma teams face real operational uncertainty. Can Jumper replicate AlphaFold at Anthropic? Honestly: unknown. AlphaFold had DeepMind infrastructure, CASP benchmarks, and years of institutional partnerships. Anthropic is a commercial LLM company pivoting into scientific AI.

Five things to watch today: Jumper's appearance and title; Mythos 5 biology access expansion; new Claude for Life Sciences connectors; Fable 5 restoration timeline; paths for non-US researchers.

Q: What is Anthropic's AI for Science event?
A: A June 30, 2026 livestream showcasing Claude across life sciences, with demos and case studies from Novartis, BMS, and Genentech.

Q: Who is John Jumper?
A: AlphaFold 2 lead and 2024 Nobel Chemistry laureate who announced his move to Anthropic on June 19, 2026 after nearly nine years at DeepMind. Role undisclosed.

Q: How fast is Claude at drug design?
A: Internal tests show Mythos 5 accelerating key steps ~10x; one fully autonomous run produced candidates for 9 of 14 protein targets.

Q: Can I use Mythos 5 for biology research right now?
A: As of June 30, only ~100 vetted US organizations have access. Fable 5 has been suspended for the general public since June 12.

Q: What is Claude for Life Sciences?
A: Anthropic's October 2025 enterprise stack connecting Claude to Benchling, PubMed, 10x Genomics, Medidata, and more — from literature to regulatory filings.

Q: Who acquired Coefficient Bio?
A: Anthropic in April 2026 for ~$400M. The sub-10-person team came from Genentech computational biology.

Six-step playbook:

1. Subscribe to Anthropic life sciences updates and STAT News for post-event product and policy changes.
2. Map your toolchain gaps against current MCP connector coverage.
3. Verify Mythos 5 eligibility or plan fallback models via LiteLLM/OpenRouter.
4. Pilot low-risk workflows first — CSR drafting and literature synthesis like NovoScribe.
5. Build multi-model routing before relying on a single vendor under export control.
6. Run agents on dedicated bare-metal Mac nodes for 24/7 isolation, audit logs, and GxP-friendly environments.

Citable data points:

• Drug design: ~10x speedup; 9/14 (64%) targets with candidates (Anthropic internal research)
• CSR writing: 90% time reduction at Novo Nordisk (official case study)
• AlphaFold scale: 214M+ structures, 190+ countries, 2M+ researchers

Sources (re-check links after upstream updates):

Anthropic: Claude for Life Sciences

Anthropic: Claude Fable 5 and Mythos 5

Novo Nordisk customer case (NovoScribe)

John Jumper Nobel lecture (2024)

Shared cloud VPS and laptops struggle with multi-day unsupervised genomics runs, sleep-induced job kills, and weak isolation for regulated workflows. For production Claude Code, MCP connectors, and bioinformatics CI that must stay online through policy swings, CALMVPS bare-metal Mac Mini rental delivers dedicated Apple Silicon, 120-second provisioning, and flexible monthly billing — swap API endpoints on an isolated node without rebuilding your entire stack when Anthropic's access rules change.

Written ahead of the June 30 livestream. Post-event updates recommended: product announcements, Jumper's official role, Fable 5 restoration, and new pharma partnerships.